Patents Examined by Anoop K. Singh
  • Patent number: 11910788
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: February 27, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Patent number: 11913022
    Abstract: Human induced pluripotent stem cells (iPSCs) can give rise to multiple cell types and hold great promise in regenerative medicine and disease modeling applications. The Inventors herein developed a reliable two-step protocol to generate human mammary-like organoids from iPSCs. Non-neural ectoderm cell-containing spheres, referred to as mEBs, were first differentiated and enriched from iPSCs using MammoCult medium. Gene expression profile analysis suggested that mammary gland function-associated signaling pathways were hallmarks of 10-d differentiated mEBs. The Inventors generated mammary-like organoids from 10-d mEBs using 3D floating mixed gel culture and a three-stage differentiation procedure. These organoids expressed common breast tissue, luminal, and basal markers, including estrogen receptor, and could be induced to produce milk protein. These results demonstrate that human iPSCs can be directed in vitro toward mammary lineage differentiation.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 27, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Ying Qu, Xiaojiang Cui, Dhruv Sareen, Armando E. Giuliano
  • Patent number: 11904001
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 20, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 11896622
    Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 13, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
  • Patent number: 11898163
    Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: February 13, 2024
    Assignees: KYOTO UNIVERSITY, SUMITOMO PHARMA CO., LTD.
    Inventors: Jun Takahashi, Daisuke Doi, Kenji Yoshida, Atsushi Kuwahara, Masayo Takahashi
  • Patent number: 11889821
    Abstract: The invention provides compositions and methods for enhanced production of immunoglobulin diversity. Specifically, the invention provides compositions and methods for making accessible a B cell receptor repertoire that has not been culled by developmental tolerance mechanisms. The invention also provides transgenic animals, cells, and antibodies resulting from these compositions and methods.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: February 6, 2024
    Assignee: TRIANNI, INC.
    Inventors: Matthias Wabl, Bao Duong, Werner Mueller
  • Patent number: 11890304
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: February 6, 2024
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 11885806
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: January 30, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paul Maciocia
  • Patent number: 11885807
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: January 30, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paul Maciocia
  • Patent number: 11884924
    Abstract: The present disclosure provides compositions of matter, methods and instruments for nucleic acid-guided nickase/reverse transcriptase fusion enzyme editing of nucleic acids in live mammalian cells.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: January 30, 2024
    Assignee: Inscripta, Inc.
    Inventors: Brian Chaikind, Aamir Mir
  • Patent number: 11884935
    Abstract: The present invention relates to a method for inducing trans-differentiation of cardiomyocytes based on exosome, and more particularly, to a method for inducing trans-differentiation of a fibroblast into a cardiomyocyte, comprising the steps of: isolating exosomes in a culture medium during a process of differentiating a stem cell into the cardiomyocyte; culturing a fibroblast in a cardiomyocyte reprogramming medium containing the isolated exosomes; and culturing the fibroblast cultured in a cardiomyocyte differentiation medium containing the isolated exosomes.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 30, 2024
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ick Chan Kwon, Sun Hwa Kim, Yoosoo Yang, Hyosuk Kim
  • Patent number: 11872243
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: January 16, 2024
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John Ramunas, Eduard Yakubov, Helen M. Blau, John Cooke
  • Patent number: 11866767
    Abstract: Provided herein are methods for simultaneous spatio-temporal measurement of gene expression and cellular activity.
    Type: Grant
    Filed: March 7, 2023
    Date of Patent: January 9, 2024
    Assignee: 10x Genomics, Inc.
    Inventors: Cedric Uytingco, Layla Katiraee, Kristen Pham
  • Patent number: 11866733
    Abstract: Methods are disclosed herein for efficiently generating human induced pluripotent stem cells (iPSC) containing a nucleic acid including a doxycycline promoter operably linked to a nucleic acid encoding Cas9. These methods include transfecting a human somatic cell with a nucleic acid molecule comprising a doxycycline promoter operably linked to a nucleic acid encoding a Cas9, and constitutive promoter operably linked to a tetracycline responsive element and inducing the somatic cell to form an iPSC, thereby producing an iPSC that can undergo CRISPR/Cas9-mediated recombination at a high efficiency. The human iPSC, or a cell differentiated therefrom, is cultured in the presence of doxycycline to induce expression of the Cas9. These cells can then be used to target in any gene of interest by introducing nucleic acids encoding sgRNAs. Induced pluripotent stem cells produced by these methods are also disclosed.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 9, 2024
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Alejandro Soto-Gutierrez, Alexandra Sylvie Collin de l'Hortet, Kan Handa, Jorge Guzman Lepe, Yang Wang, Kazuki Takeishi, Ira Jacob Fox
  • Patent number: 11866727
    Abstract: The present application provides materials and methods for treating a patient with Glycogen Storage Disease type 1a (GSD1a) both ex vivo and in vivo. In addition, the present application provides materials and methods for modulating the expression, function, and/or activity of the glucose-6-phosphatase, catalytic (G6PC) and/or the glucose-6-phosphatase (G6Pase) protein in a cell by genome editing.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: January 9, 2024
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Ante Sven Lundberg, Kirsten Leah Beaudry
  • Patent number: 11858976
    Abstract: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: January 2, 2024
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Tong Zhang, Charles L Sentman
  • Patent number: 11859208
    Abstract: This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: January 2, 2024
    Assignee: Emory University
    Inventors: Edmund Waller, Anna Morris, Christopher Petersen, Jian-Ming Li, Reema Panjwani, Jingxia Li
  • Patent number: 11859204
    Abstract: A mold for producing a hydrogel support for a 3-dimensional (3D) cell culture, includes: an upper mold comprising a base and a plurality of upper unit molds protruding downward from the base to form accommodating portions of a female type corresponding to shapes of hydrogel supports, having through holes at bottoms thereof, and patterned at a lower portion of the base; a lower mold where a plurality of lower unit molds are patterned, the plurality of lower unit molds formed in a female type to respectively accommodate the plurality of upper unit molds protruding downward and having sealed lower portions; and an ejecting unit for separating, from the accommodating portions of the plurality of upper unit molds, the hydrogel supports that are coagulated after being inserted into the through holes respectively formed in the plurality of upper unit molds.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: January 2, 2024
    Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Sik Yoon, Ye Seon Lim, Ye Jin Ok, Sun Young Hwang, Kang Oh Lee, Seung Soo Lee
  • Patent number: 11851653
    Abstract: The present application provides materials and methods for treating a patient with Alpha-1 antitrypsin deficiency (AATD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing the SERPINA1 gene in a cell by genome editing.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 26, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Chad Albert Cowan, Roman Lvovitch Bogorad, Jeffrey Li, Ante Sven Lundberg, Matthias Johannes John, Jeffrey William Stebbins, Thao Thi Nguyen
  • Patent number: 11849719
    Abstract: The present disclosure relates to an improved process of organ perfusion with vitrifiable concentrations of cryoprotective agents. In one implementation, the method may include perfusing an organ with a first solution containing a vitrifiable concentration of cryoprotectant at a temperature at or above ?10° C. and perfusing the organ with a second solution containing a higher concentration of cryoprotectant than the first solution. The first solution may be adapted to vitrify at a cooling rate of less than 20° C./min, and the second solution may be adapted to vitrify at a cooling rate of less than 5° C./min. The perfusing with the second solution may begin at or above ?10° C. and cause the organ to decline in temperature to below ?10° C.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: December 26, 2023
    Assignee: 21st Century Medicine, Inc.
    Inventor: Gregory M. Fahy